CSIMarket
 
Tyra Biosciences Inc   (TYRA)
Other Ticker:  
 
 
Price: $17.5000 $-0.25 -1.408%
Day's High: $17.73 Week Perf: -10.26 %
Day's Low: $ 17.16 30 Day Perf: -9.19 %
Volume (M): 615 52 Wk High: $ 20.67
Volume (M$): $ 10,756 52 Wk Avg: $14.64
Open: $17.51 52 Wk Low: $10.38



 Market Capitalization (Millions $) 750
 Shares Outstanding (Millions) 43
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 0

Tyra Biosciences Inc
Tyra Biosciences Inc. is a biotechnology company that specializes in discovering and developing a range of cancer therapies. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Tyra Biosciences is focused on identifying and developing small molecule therapies that target specific oncogenic signaling pathways. The company has a team of experienced scientists and researchers who are dedicated to advancing the understanding of cancer biology and developing new treatments.

The company's lead product candidate is TYRA-101, which is a small molecule inhibitor of the Met receptor. Met is a protein that plays a critical role in promoting cancer growth and metastasis. TYRA-101 is designed to block Met signaling, which may lead to the inhibition of tumor growth and the suppression of metastases.

In addition to TYRA-101, the company is also developing a pipeline of other small molecule inhibitors that target various pathways involved in cancer progression. These include inhibitors of the EGFR, PDGFR, and VEGFR signaling pathways, which are implicated in several types of cancer.

Tyra Biosciences is committed to advancing the understanding of cancer biology and developing innovative therapies that can improve the lives of patients with cancer. The company has built a strong scientific foundation and is dedicated to bringing new treatments to patients as quickly as possible.


   Company Address: 2656 State Street Carlsbad 92008 CA
   Company Phone Number: 728-4760   Stock Exchange / Ticker: NASDAQ TYRA
   TYRA is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Tyra Biosciences Inc

Tyra Biosciences Inc's Surging Working Expenses Raise Concerns in Q3 2023 Earnings Season


As the July to September 30, 2023 reporting season resumes, the latest financial results have raised concerns for many investors, particularly in the Major Pharmaceutical Preparations industry. With the recent disclosure of a significant operating loss by Tyra Biosciences Inc during the third quarter of 2023, it is imperative to analyze the implications and potential road ahead for this company.
Tyra Biosciences Inc reported an operating loss of $-23.963 million, marking a significant deterioration from the $-13.645 million loss in the same quarter last year. This decline has provoked questions among investors about the company's ability to generate revenue in the near future. The absence of revenue is the most notable aspect of Tyra Biosciences Inc's third-quarter earnings report in 2023. Furthermore, the company faced a $-21.152 million shortfall, which has expanded considerably from $-12.509 million in the corresponding period in the previous year.

Tyra Biosciences Inc

Underdog Tyra Biosciences Inc Challenges the Status Quo with Narrowed Losses in Q2 2023

Trailing the big players in the Major Pharmaceutical Preparations industry, Tyra Biosciences Inc has emerged as a lesser-known entity that is making waves with its results. The company recently revealed an operating deficit of $-16.014 million for the second quarter of 2023. While the specific revenue figures have not been disclosed yet, comparing it to the company's performance in the second quarter of 2022 helps put the latest results into perspective. In the same quarter last year, Tyra recorded an operating deficit of $-15.428 million.
One positive aspect to note is that the losses have been trimmed compared to the previous year, indicating progress for the company. In the second quarter of 2023, the deficit stood at $-13.272 million, whereas in the second quarter of 2022, it was $-15.095 million. This improvement in the bottom-line is a significant takeaway from the second quarter of 2023 earnings season.

Tyra Biosciences Inc

Tyra Biosciences Inc. Sees Significant Growth in Q1 2023 despite Operating Loss of $-14.334 Million

In the world of finance, the earnings reports of big companies are always closely watched and analyzed. However, there are often smaller and lesser-known entities that can often get overlooked. One such entity is Tyra Biosciences Inc, which recently reported that it had an operating loss of $-14.334 million for the first quarter of 2023.
Despite this negative news, there were some positive developments for the company. Firstly, it was noted that the current operational instance has actually overshadowed the same category in the financial interval ending March 31, 2022. This means that Tyra Biosciences is moving in the right direction when it comes to the research period.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com